Publications in collaboration with researchers from Eli Lilly and Company (1)

2017

  1. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

    The Lancet, Vol. 389, Núm. 10086, pp. 2317-2327